“The approval of VYVGART for gMG patients in Australia is an important milestone for patients who are seeking access to a treatment with the potential to allow them to return to normal activities of daily living,” said Kathryn Evans, the general manager of argenx Australia. …
argenx secures TGA approval of precision therapy for rare disease
February 28, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Take the right learning from a situation that was mostly about ministerial intervention
February 28, 2025 - - Latest News -
Companies building their 'Kosi Challenge' totals with two weeks to go
February 28, 2025 - - Latest News -
argenx secures TGA approval of precision therapy for rare disease
February 28, 2025 - - Latest News -
The Cell and Gene Catalyst mobilises 71 leaders to accelerate industry growth
February 28, 2025 - - Latest News -
Health department appoints consultant to support HTA Review implementation group
February 28, 2025 - - Latest News -
US biotech industry welcomes proposed change to price negotiation power
February 27, 2025 - - Latest News -
HTA go-slow on newborn screening leaves parents waiting and waiting
February 27, 2025 - - Latest News